Nesiritide Pregnancy and Breastfeeding Warnings
Nesiritide is also known as: Natrecor
Nesiritide Pregnancy Warnings
Animal reproductive studies have failed to reveal evidence of adverse effects on live births or fetal development. There are no controlled data in human pregnancy.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.
The manufacturer makes no recommendation regarding use during pregnancy.
US FDA pregnancy category: Not assigned.
Risk Summary: Insufficient data exist to assess a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes during use in pregnant women.
Nesiritide Breastfeeding Warnings
The manufacturer makes no recommendation regarding use during lactation.
Excreted into human milk: Unknown
Excreted into animal milk: Unknown
Comments: The effects in the nursing infant are unknown.
See also
References for pregnancy information
- "Product Information. Natrecor (nesiritide)." Scios Inc (2022):
References for breastfeeding information
- "Product Information. Natrecor (nesiritide)." Scios Inc (2022):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.